Download
s00432-021-03803-3.pdf 978,34KB
WeightNameValue
1000 Titel
  • Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial
1000 Autor/in
  1. Öcal, Osman |
  2. Rössler, Daniel |
  3. Gasbarrini, Antonio |
  4. Berg, Thomas |
  5. Klümpen, Heinz-Josef |
  6. Bargellini, Irene |
  7. Peynircioglu, Bora |
  8. van Delden, Otto |
  9. Schulz, Christian |
  10. Schütte, Kerstin |
  11. Iezzi, Roberto |
  12. Pech, Maciej |
  13. Malfertheiner, Peter |
  14. Sangro, Bruno |
  15. Ricke, Jens |
  16. Seidensticker, Max |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-09-20
1000 Erschienen in
1000 Quellenangabe
  • 148(9):2487-2496
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00432-021-03803-3 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349099/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Gadoxetic acid uptake on hepatobiliary phase MRI has been shown to correlate with ß-catenin mutation in patients with HCC, which is associated with resistance to certain therapies. This study aimed to evaluate the prognostic value of gadoxetic acid uptake on hepatobiliary phase MRI in patients with advanced HCC receiving sorafenib.!##!Methods!#!312 patients with available baseline hepatobiliary phase MRI images received sorafenib alone or following selective internal radiation therapy (SIRT) within SORAMIC trial. The signal intensity of index tumor and normal liver parenchyma were measured on the native and hepatobiliary phase MRI images, and relative tumor enhancement higher than relative liver enhancement were accepted as high gadoxetic acid uptake, and its prognostic value was assessed using univariate and multivariate Cox proportional hazard models.!##!Results!#!The median OS of the study population was 13.4 (11.8-14.5) months. High gadoxetic acid uptake was seen in 51 (16.3%) patients, and none of the baseline characteristics was associated with high uptake. In univariate analysis, high gadoxetic acid uptake was significantly associated with shorter overall survival (10.7 vs. 14.0 months, p = 0.005). Multivariate analysis confirmed independent prognostic value of high gadoxetic acid uptake (HR, 1.7 [1.21-2.3], p = 0.002), as well as Child-Pugh class (p = 0.033), tumor diameter (p = 0.002), and ALBI grade (p = 0.015).!##!Conclusion!#!In advanced HCC patients receiving sorafenib (alone or combined with SIRT), high gadoxetic acid uptake of the tumor on pretreatment MRI, a surrogate of ß-catenin mutation, correlates with shorter survival. Gadoxetic acid uptake status might serve in treatment decision-making process.
1000 Sacherschließung
lokal Gadoxetic acid
lokal Molecular Imaging [MeSH]
lokal ß-Catenin
lokal Liver Neoplasms/diagnostic imaging [MeSH]
lokal Original Article – Clinical Oncology
lokal Humans [MeSH]
lokal Sorafenib [MeSH]
lokal Hepatocellular carcinoma
lokal Carcinoma, Hepatocellular/pathology [MeSH]
lokal Gadolinium DTPA [MeSH]
lokal Retrospective Studies [MeSH]
lokal Contrast Media [MeSH]
lokal Carcinoma, Hepatocellular/drug therapy [MeSH]
lokal Sorafenib
lokal Radioembolization
lokal Sirtuins [MeSH]
lokal Carcinoma, Hepatocellular/diagnostic imaging [MeSH]
lokal Liver Neoplasms/pathology [MeSH]
lokal WNT
lokal Magnetic Resonance Imaging/methods [MeSH]
lokal Biomarkers [MeSH]
lokal Catenins [MeSH]
lokal Liver Neoplasms/drug therapy [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/w5ZjYWwsIE9zbWFu|https://frl.publisso.de/adhoc/uri/UsO2c3NsZXIsIERhbmllbA==|https://frl.publisso.de/adhoc/uri/R2FzYmFycmluaSwgQW50b25pbw==|https://frl.publisso.de/adhoc/uri/QmVyZywgVGhvbWFz|https://frl.publisso.de/adhoc/uri/S2zDvG1wZW4sIEhlaW56LUpvc2Vm|https://frl.publisso.de/adhoc/uri/QmFyZ2VsbGluaSwgSXJlbmU=|https://frl.publisso.de/adhoc/uri/UGV5bmlyY2lvZ2x1LCBCb3Jh|https://frl.publisso.de/adhoc/uri/dmFuIERlbGRlbiwgT3R0bw==|https://frl.publisso.de/adhoc/uri/U2NodWx6LCBDaHJpc3RpYW4=|https://frl.publisso.de/adhoc/uri/U2Now7x0dGUsIEtlcnN0aW4=|https://frl.publisso.de/adhoc/uri/SWV6emksIFJvYmVydG8=|https://frl.publisso.de/adhoc/uri/UGVjaCwgTWFjaWVq|https://frl.publisso.de/adhoc/uri/TWFsZmVydGhlaW5lciwgUGV0ZXI=|https://frl.publisso.de/adhoc/uri/U2FuZ3JvLCBCcnVubw==|https://frl.publisso.de/adhoc/uri/Umlja2UsIEplbnM=|https://orcid.org/0000-0002-2481-5410
1000 Hinweis
  • DeepGreen-ID: 4b6afd73240a43038b2f428ca99becf2 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6446902.rdf
1000 Erstellt am 2023-04-28T14:31:27.261+0200
1000 Erstellt von 322
1000 beschreibt frl:6446902
1000 Zuletzt bearbeitet 2023-10-20T19:13:51.763+0200
1000 Objekt bearb. Fri Oct 20 19:13:51 CEST 2023
1000 Vgl. frl:6446902
1000 Oai Id
  1. oai:frl.publisso.de:frl:6446902 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source